Skip to main content
Uncategorized

Supragen, a new spin-off at IRB Barcelona

By 6 de October de 2011November 18th, 2020No Comments
< Back to news
 06.10.2011

Supragen, a new spin-off at IRB Barcelona

Roger Gomis, ICREA researcher at the Institute of Research in Biomedicine (IRB Barcelona), based at the Barcelona Science Park– has set up the spin-off Supragen. With the support of IRB Barcelona and the Institució Catalana de Recerca i Estudis Avançats (ICREA), this initiative is the second biotech company to emerge from the institute since June and the third since this centre was set up towards the end of 2005.


Supragen seeks to develop a diagnostic kit and also new treatments for breast cancer metastasis. Registered in Barcelona, this new company is supported by base capital from the founding partners and expects to close negotiations for capital risk funding mid October.

Supragen is the result of the research performed by Gomis’ team in the Growth Control and Cancer Metastasis Lab at IRB Barcelona, and this new company joins the biotech Omnia Molecular, founded in 2005 by Lluís Ribas de Pouplana (ICREA-IRB Barcelona), and Iproteos, founded in 2011 by Ernest Giralt (IRB Barcelona-UB) and Teresa Tarragó (IRB Barcelona).

For further information